Senores
Committed to Global Wellness!

Date: July 27, 2026

To, Sr. General Manager Listing Department **BSE Limited** Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001 **BSE Scrip Code: 544319**	To, Sr. General Manager Listing Department **National Stock Exchange of India Limited** Exchange Plaza, C-1, Block G Bandra Kurla Complex Bandra (E), Mumbai – 400 051 **NSE Symbol: SENORES**

Sub.: Investor Presentation for Q1FY27

Dear Sir/Madam,

In terms of Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and our intimation dated July 21, 2026 regarding the Earnings Conference Call, we enclose herewith the Investor Presentation for Q1FY27.

The aforesaid information is also being hosted on the Company's website at www.senorespharma.com.

You are requested to take the same on record.

Thanking you.

For Senores Pharmaceuticals Limited

DEVAL RAJNIKANT SHAH
Digitally signed by DEVAL RAJNIKANT SHAH
Date: 2026.07.27 15:51:03 +05'30'

Deval Rajnikant Shah
Whole Time Director & CFO
DIN: 00332722

Enclosure: As above

Senores Pharmaceuticals Limited
1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com
W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

Investor Presentation

July 2026

Senores
Committed to Global Wellness!

Safe Harbor

This presentation and the accompanying slides (the "Presentation"), which have been prepared by **Senores Pharmaceuticals Limited** (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.

Financial & Operational Highlights
Q1 FY27

Key Highlights Q1FY27

- Consistently delivering robust performance with Revenues for Q1FY27 growing **by 36% Y-o-Y**
- Strong revenue growth delivered in Regulated & Emerging markets with revenue growth of **42% & 30% respectively** on a Y-o-Y basis
- EBIDTA for Q1FY27 **grew by 87%** with margin expansion of **~800 bps** on a Y-o-Y basis
- **Robust addition in approved and pipeline products** providing high growth visibility for years to come
- Steady focus on manufacturing & cost efficiency enabling **sustainable margin growth & expansion**
- Robust & diversified business model supported by **Strong & Experience management team**

Senores Pharmaceuticals
Committed to Global Wellness!

INDIA

Ratnatris Pharmaceuticals Pvt. Ltd.
(A subsidiary of
Senores Pharmaceuticals Ltd.)

APNAR PHARMA PVT. LTD.
(A subsidiary of
Senores Pharmaceuticals Ltd.)

USA

Senores Pharmaceuticals Inc.
(Wholly Owned Subsidiary)

Havix Group Inc.
D/B/A Aavis Pharmaceuticals
(A subsidiary of
Senores Pharmaceuticals Ltd.)

Zoraya Pharmaceuticals, LLC
(A subsidiary of
Senores Pharmaceuticals Inc.)

Amerisyn LLC
(A subsidiary of Senores
Pharmaceuticals Inc.)

Regulated Market Owned Product Portfolio & Visibility

Senores
Committed to Global Wellness!

	Owned ANDAs Q1FY26	Owned ANDAs Q1FY27	Corresponding ANDA Products* Q1FY26	Corresponding ANDA Products* Q1FY27
Approved ANDAs	30	**58**	70	**187**
Commercialized ANDAs	12	**23**	24	**51**
Yet To Launch	18	**35**	46	**136**
ANDAs Under Pipeline	31	**39**	57	**119**

Huge Opportunity

Scaled up Own ANDAs by **2x** and Corresponding ANDA products by nearly **2.5x** over the past 12 months

35 ANDAs with Corresponding 136 ANDA Products to be launched with our target share of USD **740 mn+ (gross)**

Robust Pipeline under development of **39 molecules** with **119 unique strengths**

*ANDA Products represents individual strengths associated with an ANDA

CDMO / CMO & Emerging Market Opportunity

	Products Q1FY26	Products Q1FY27	Corresponding ANDA Products* Q1FY26	Corresponding ANDA Products* Q1FY27
CDMO/ CMO Commercialized Products	15	**16**	27	**34**
CDMO / CMO Pipeline Products	15	**37**	53	**120**

Huge Opportunity

CDMO/CMO business focused on specialty, **government supplies** and **controlled substances**.

Uniquely positioned in USA & India to provide **end-to-end solutions** from development to commercialization.

Significantly **enhances efficiency, scale & utilization**, leading to **better operating leverage**.

Emerging Markets Portfolio

Approved Products



Products under Registration



Significant expansion of the **Approved and Pipeline** product portfolio across **40+ countries** creating a **strong runway for future growth.**

Regulated Markets | Emerging Markets

*ANDA Products represents individual strengths associated with an ANDA

Consolidated Financial Highlights – Q1 FY27

Revenue (₹ Crs)



EBITDA (₹ Crs)



PAT (₹ Crs)



Gross Margin (%)



EBITDA Margin (%)



PAT Margin (%)



Segmental Financial Highlights – Q1 FY27

Segment Revenue (₹ Crs)	Q1FY27	Q1FY26	Y-o-Y	FY26	FY25	Y-o-Y
Regulated Markets	**127.8**	90.1	***41.9%***	427.4	244.8	*74.6%*
Emerging Markets	**37.6**	29.0	***29.6%***	145.0	121.2	*19.7%*
Branded Generics	**8.0**	8.2	***-2.4%***	40.0	8.2	*385.3%*
Others (Incl. API Sales)	**6.8**	5.2	***29.2%***	20.3	36.2	*-43.9%*
Total Revenue	**180.2**	132.6	***35.9%***	**632.6**	410.4	***54.1%***

- **Regulated Markets -** EBIDTA Margin for Q1 FY27 stood at ~40%. Regulated Markets contributed to **71% of total revenue** in Q1FY27
- **Emerging Markets -** EBIDTA Margin for Q1 FY27 stood at ~14%. Emerging Markets contributed **21% of total revenue** in Q1FY27

Consolidated Profit & Loss Account – Q1 FY27

Consolidated P&L (₹ Crs)	Q1 FY27	Q1 FY26	*Y-o-Y*	FY26	FY25	Y-o-Y
Revenue from Operations	**180.2**	**132.6**	***35.9%***	**632.6**	**410.3**	**54.2%**
Cost of Goods Sold	**65.7**	**61.4**		**251.7**	**180.7**	
Gross Profit	**114.5**	**71.3**	***60.6%***	**381.0**	**229.6**	**65.9%**
Gross Margin (%)	**63.5%**	**53.7%**	***980 bps***	**60.2%**	***56.0%***	***420 bps***
Employee Cost	29.9	21.7		112.3	60.4	
Other Expenses	30.8	20.8		100.4	67.5	
EBITDA	**53.8**	**28.8**	***87.0%***	**168.3**	**101.8**	**65.3%**
EBITDA Margin (%)	**29.8%**	**21.7%**	***810 bps***	**26.6%**	***24.8%***	***180 bps***
Other Income	2.8	8.7		47.1	7.2	
Depreciation	9.9	6.0		31.3	16.8	
Finance Cost	7.2	5.0		25.0	21.6	
PBT	**39.5**	**26.5**	***48.9%***	**159.1**	**70.6**	**125.3%**
Tax Charge / (Credit)	9.0	5.3		37.6	12.2	
Profit after Tax	**30.4**	**21.2**	***43.7%***	**121.5**	**58.3**	**108.4%**
PAT Margin (%)	**16.9%**	**16.0%**	***90 bps***	**19.2%**	***14.2%***	***500 bps***
Minority Interest	-0.3	1.5		6.2	-0.2	
Profit after Tax and Minority Interest	**30.7**	**19.7**	***55.6%***	**115.4**	**58.5**	**97.0%**
PAT Margin (%) after Minority Interest	**17.0%**	**14.9%**	***220 bps***	**18.2%**	**14.3%**	**390 bps**

Update on Utilization of Funds from IPO

No.	Object as per Offer Document	Amount as proposed in the Offer Document and as Revised (₹ Crs)	Amount utilized till June 2026 (₹ Crs)	Amount unutilized as on 30th June 2026 (₹ Crs)
1	Investment in one of our Subsidiaries, Havix, to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility	107.0	6.98	100.0
2	Re-payment/pre-payment, in full or in part, of certain borrowings availed by our Company (Refer Note A below)	73.1	73.1	0.0
3	Investment in our Subsidiary, namely, Havix, for re- payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiaries	20.2	20.2	0.0
4	Funding the working capital requirements of our Company	43.3	43.26	0.0
5	Investment in our Subsidiaries, namely, Senores Pharma Inc. and Ratnatris Pharmaceuticals Pvt Ltd. to fund their working capital requirements	59.5	59.48	0.0
6	Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes (Refer Notes A & B below)	161.9	161.63	0.3
7	Offer expenses (Refer Note A below)	35.0	34.8	0.2
	Total	**500.0**	**399.5**	**100.5**

Growth Strategies

Growth Strategies

Inorganic growth through **synergistic acquisitions**

Significantly enhance market presence in **North America** & **other Regulated Markets**

Integrated approach by enhancing capabilities for **backward integration**

Launch products with the **potential of NDA approval** in the **US**

Strategic alliance for **CMO/CDMO** in **Regulated Markets**

Expanding into new ventures of **Direct B2C** and **Government Sales**

About Senores Pharmaceuticals Limited

Introduction to Senores Pharmaceuticals

Brief Overview

Global Research driven **Formulation Focused** company engaged in **developing** & **manufacturing** of pharmaceutical products predominantly for the **Regulated Markets of the US, Canada, UK and others** across various **therapeutic areas**

Niche Product Identification

Company focusses on **identification, development** and **commercialization** of products

R&D Capabilities

Identification, development & manufacturing of diverse range of **specialty, underpenetrated & complex** pharmaceutical products across therapeutic areas and dosage forms

Manufacturing Facilities

1 USFDA approved Formulation facility in Atlanta, US
2 Formulation facilities in Gujarat, India – out of which 1 is USFDA approved
2 API manufacturing facilities in Gujarat, India

Partnerships

Partnerships with leading pharmaceutical companies across Regulated as well as Emerging Markets

At a Glance

Disclaimer: Map not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.

Corporate Structure

Senores Pharmaceuticals Inc.	**Senores Pharmaceuticals Inc.** Marketing cum ANDA Holding Company	US based company holding ANDAs and mutually exclusive marketing relationships with customers	100% Subsidiary
AAVIS Pharmaceuticals	**Senores Pharmaceuticals Inc.** Marketing cum ANDA Holding Company	Engaged in the Contract Development & Manufacturing of Generic Pharmaceutical Formulations for the US, Canada	73.28% [1] Subsidiary
Ratnatris Pharmaceuticals	**Ratnatris Pharmaceuticals Pvt Ltd.** Caters to Emerging Market	Development, Manufacturing and Marketing of Generic Pharmaceutical Formulations	69% Subsidiary
APNAR PHARMA PVT. LTD. (A subsidiary of Senores Pharmaceuticals Ltd.)	**Apnar Pharma Pvt. Ltd.** Caters to Regulated Market	Licensed Manufacturer Serving Regulated Markets. Operates a manufacturing facility at Gujarat with 5 ANDAs approved	75% Subsidiary
AMERISYN	Enters U.S. Federal Market via Strategic **JV - Amerisyn**	Senores Pharma's U.S. JV, Amerisyn, enables direct access to high-barrier federal and defense markets, driving future growth.	70% stake
ZORAYA PHARMACEUTICALS	**Zoraya Pharma** is a B2C arm for our US Market	Forward integration for the products which are manufactured at Havix & Apnar and marketed in US market.	51% stake

Note 1 : 57.69% held by the holding company & 15.59% held by it's wholly owned subsidiary company named Senores Pharmaceuticals Inc

Four Business Segments

FY26 Revenue

₹ 180 Crs

Regulated Markets Business

Primarily serves the **US, Canada** and **United Kingdom**

USFDA approved **facility in Atlanta, US and Gujarat, India**

Approved - **58** ANDAs with **187** Strengths

Commercialized – **23** ANDAs with **51** Strengths

Pipeline Products – **39** Molecules with **119** Strengths

APNAR PHARMA PVT. LTD.
(A subsidiary of Senores Pharmaceuticals Ltd.)

Emerging & Mid-Tier Markets Business

Develop & manufacture pharmaceutical products for the Emerging & Mid-Tier Markets

WHO-GMP approved **facility at Chhatral, Gujarat**

Present in **40+ Countries**

Approval for manufacturing facility from regulatory bodies of **10 Countries**

Product registration for **513 Products**

Product applications filed for **942 Products**

API Business

Manufacture APIs and caters to the **domestic market** and **SAARC countries**

Naroda facility compliant with Indian GMP

Commercialized **17 APIs**

Branded Generics Business

Supply of critical care injectables across **India** to various **hospitals** through the distributors

Field presence with **104 employees**

Launched **60 Products**

Distinct Specialty & Complex Product Portfolio Built in a Short Span for Regulated Markets

Demonstrated Capability to Propel Products from Conception to Commercialization

Product Identification

- Data Analysis – IQVIA, Symphony & Other Data
- Competitive Landscape
- Product Feasibility
- CGT Applicability

2-3 Months

Product Development

- R&D to establish API Equivalency
- Formulation Development
- BE Studies
- Stability Testing

18-20 Months

Commercial

Partner Finalization	Concurrent Process
Dossier Compilation	1-2 Months
Filing	Immediately post-compilation
Approval	10-15 Months post-filing
Launch	Immediately post-approval

Key Strengths of the Company

Distinct **Specialty and Complex Product Portfolio** built in a short span for **Regulated Markets**

Direct access to the **US Government supplies** through its subsidiary

Enabling **Forward Integration** via our subsidiary, catering directly to **B2C** and **Veterinary market**

Senores
Committed to Global Wellness!

Strong R&D capabilities driving differentiated portfolio of products

US FDA approved facility in the US & India catering to the **Regulated** & **Semi-Regulated Markets**
WHO- GMP compliant facility **in India** catering to **Emerging Markets**

Professional & Experienced management teams for the diverse business verticals

Key Events & Milestones

Senores Committed to Global Wellness!

2017

Senores Pharmaceuticals

Incorporated as "**Senores Pharmaceuticals Pvt. Ltd.**" in India.

2021

Entered into a new segment of API with **acquisition** of **Ratnagene Lifescience Pvt. Ltd.**[1]

Senores Committed to Global Wellness! API Division

2021

Senores Pharmaceuticals Inc.

Incorporated a wholly owned subsidiary, **Senores Pharmaceuticals Inc** in the US

2023

Acquired majority stake in **Havix**, enhancing the ability to serve Regulated Markets through **USFDA approved facility** in **US**

AAVIS PHARMACEUTICALS

2023

Ratnatris Pharmaceuticals

Consolidated presence in emerging markets by acquiring shares in **Ratnatris Pharmaceuticals Pvt. Ltd.**

2024

Successful Listing on Stock Exchanges in India on **BSE & NSE**

Senores Pharmaceuticals

2025

APNAR PHARMA PVT. LTD. (A subsidiary of Senores Pharmaceuticals Ltd.)

ZORAYA PHARMACEUTICALS

Acquired a **51% stake in Zoraya Pharmaceuticals**, LLC (Nov 2025)

Acquired **75% stake in Apnar Pharmaceuticals Pvt. Ltd**

2026

Amerisyn LLC - Strategic **joint venture in the U.S**, for Federal and defense sector supplies

AMERISYN

Note: 1: Now merged with Senores Pharmaceuticals Limited with the appointed date being January 1, 2024

Presence in Regulated Markets through Long-term marketing arrangements

Senores
Committed to Global Wellness!

MARKETED PRODUCTS

Business Model

Identify, Develop & Commercialize specialty & complex niche products in mid-market range

- **Long-term Marketing & Distribution Agreements**
- Strength lies in taking a product from **conceptualization to commercialization**
- **58** Approved ANDAs with **187** strengths
- **23** Commercialized ANDAs with **51** strengths

AMERISYN
Senores Pharmaceuticals Inc.
ZORAYA PHARMACEUTICALS

CDMO / CMO

Business Model

Customized formulation, development & manufacturing capabilities for customers

- **Partner with CDMO customers early** in the drug development process
- **Recurring Revenue** with **Steady & Predictable Cash Flows**
- Contracts for more than **40** products in **US, Canada, UK, South Africa, UAE, Israel, Denmark, Saudi Arabia & Vietnam.**
- Eligible for manufacturing formulations having **controlled substances**
- **Complied** for **catering** to **government supplies** in the **US**

APNAR PHARMA PVT. LTD.
(A subsidiary of Senores Pharmaceuticals Ltd.)
AAVIS PHARMACEUTICALS

Pharmaceutical companies increasingly favor partnering with one-stop-shop solution providers that seamlessly integrate both development and manufacturing services

Presence in the Emerging & Mid-Tier Markets with Portfolio including Specialty and Niche Products

Senores
Committed to Global Wellness!

40+
Countries Marketed

1,455
Total Products

513
Product Registrations

942
Product Applications Filed



85 | 38
Registered | Filed

194|425
Registered | Filed

41 |168
Registered |Filed

190 |297
Registered | Filed

3|13
Registered |Filed

Entered EU and Other Mid-Tier Markets with 15 Approved Products as of June 2026

Special Focus

Niche & Specialty patented products in the US with early launch opportunity in Emerging Markets

Sugammadex

Ferric Carboxymaltose

Tofacitinib

Sacubitril + Valsartan

Apixaban

Eltrombopag Olamine

Diverse Business Models

- P2P Model
- Distributor Model
- CDMO Model
- Own Brands

Top Emerging Markets

Philippines	Peru	Ghana	Nigeria	Myanmar	Guatemala	Kenya

Professional and Experienced Management Team (1/2)

Swapnil Jatinbhai Shah
Promoter & Managing Director

- Nearly 2 decades of experience in the pharma sector
- Part of the core management team & leads overall company functions: product portfolio, corporate strategy, business development, strategic management

Sanjay Shaileshbhai Majmudar
Chairman & Non-Executive, Non- Independent Director

- 40+ years of experience
- Director on the board of AIA Engineering Ltd., Ashima Ltd., M&B Engineering Ltd. & Welcast Steels Ltd.

Deval Rajnikant Shah
Whole-Time Director & CFO

- 40+ years of experience in Pharma, Engineering & Chartered Accountancy
- Previously associated with SAI Consulting Engineers Pvt. Ltd. as CFO

Chetan Bipinchandra Shah
Whole-Time Director & COO

- 25+ years of experience in Pharma
- Previously associated with Torrent Pharma & Cadila Pharma. Also associated with Reliance Retail Ltd., Reliance Fresh Ltd. & Reliance Corporate IT Park Ltd.

Jitendra Babulal Sanghvi Non-Executive, Non-Independent Director

- 17+ years of Total experience
- Spearheading Ratnatris Pharmaceuticals as the Director for nearly two decades, since Aug 11, 2009.

Ashokkumar Vijaysinh Barot
Promoter, Non-Executive, Non- Independent Director

- 21+ years of Pharmaceutical experience
- Non-Executive Director on the board of Di-Cal Pharma Pvt. Ltd. Since Nov 6, 2008. Registered pharmacist with the state pharmacy council of Gujarat

Professional and Experienced Management Team (2/2)

Senores
Committed to Global Wellness!

Jignesh Desai
President - Finance

- 30+ years of experience in finance and accounting
- Qualified CA by profession
- Previously associated with Cadila Pharmaceuticals, Gokul Refoil & Solvent, Zydus Cadila, and Ashima Denim.

Gautam Shah
President - US Operations

- 30+ years of experience in pharmaceutical industry
- Held leadership roles at leading pharmaceutical companies like Cipla, Sun Pharma, Caraco Pharmaceutical, Dow Corning, Accord Healthcare, etc.

Jatin Gajjar
Chief Technology Officer

- 30+ years of experience in pharmaceutical technology, manufacturing operations, and product development
- Previously associated with Sun Pharmaceutical Industries, Alembic, Zydus Cadila, Torrent Pharma and Aventis Pharma

H. S. Shaktawat
Assistant Vice President - Human Resources

- 25+ years of experience in strategic HR leadership, talent management, and organizational development.
- Previously associated with Sanghi Industries, Cadila Pharmaceuticals, Torrent Pharmaceuticals, Ratnamani Metals & Tubes.

Deepak Jain
Vice President Regulatory Affairs

- Nearly 2 decades of Pharmaceutical experience
- Previously Associated with Cadila Healthcare Ltd. as Deputy General Manager

Sanjay Moralwar
Head - IT

- 36+ years of experience
- Previously associated with CMS Computers Pvt. Ltd, Bajaj Auto Limited, Torrent Pharmaceuticals and Zydus Lifesciences.

Mehul Patel
General Manager – Project Management

- Nearly 2 decades in Formulation Development, technology transfer, and launch execution for Complex Oral Solid products.
- Previously associated with Zydus, Cadila, Wockhardt, etc.

Strong R&D Capabilities Driving Differentiated Product Portfolio

Oral Solids
ORS
Injectables
Oral Liquids
API



R&D Site 1 - USA

In-House R&D in US for Controlled Substances

R&D Site 2 - India

Consolidating R&D activities at Ahmedabad. R&D Centre spread around 11,750 sq. ft

R&D Site 3 - India

Multi-dosage form R&D capabilities and a state-of-the-art Quality Control laboratory for testing and release of all finished products

R&D Site 1 - USA

Internal research Information available on subscribed databases

Team

107 people & 3 members having doctoral qualifications

Margin

The focus on R&D has allowed the company to maintain high profit margins compared to its industry peers

Accredited FDF Manufacturing Facilities (1/2)

Atlanta Facility

Facility

3
Manufacturing Lines

185,300 Sq. Ft.
Total Area

OSD

1.5 Bn units
Annual Installed Capacity

Strong Regulatory Track Record

USFDA Approved	**5 USFDA**| Received **no Form 483** & **8 Customer Audits**
DEA Compliant	**Eligible** for **Manufacturing Controlled Substances**
BAA Compliant	Ability to **caters to Government Supplies**

Ahmedabad, Chhatral Facility

378,943 Sq. Ft.
Total Area

12
Manufacturing Lines

4
Dosage Forms

General Oral Dosage	Injectables	Beta Lactum Orals
1,397.96 Mn Annual Installed Capacity	**49.92 Mn** Annual Installed Capacity	**511.68 Mn** Annual Installed Capacity

Facility Approvals

KUWAIT	MOH
CAMBODIA	MOH
TANZANIA	MOH
IVORY COAST	DPM
KENYA	PPB
PHILIPPINES	FDA
NIGERIA	NFDAC
PERU	DIGEMID
ZAMBIA	MOH
LIBERIA	MOH

Accredited FDF Manufacturing Facilities (2/2)

Apnar Pharma Plant

- ✓ Manufacturing facility commenced in 2021 & **USFDA Approval received in September 2022**
- ✓ 2 land parcel available of total land area of **~49,250 Sq. Mts**.
- ✓ Facility constructed on 1 plot (~4,500 Sq. Mts) with construction of ~40,000 Sq. Ft. Larger plot with ample land **available for future expansion**
- ✓ Employees Strength **– 50+ Employees**
- ✓ Approved ANDAs/Products – **5 ANDAs/15 Strengths**
  - Total Addressable Market of acquired products – **~$722 Mn**
  - Currently catering to **US, UK and Canada**
- ✓ The facility integrates manufacturing with strong multi-dosage form **R&D capabilities** and an advanced **Quality Control Lab** dedicated to testing and releasing all finished products.
- ✓ Facility is compliant with **clean rooms** for expansion into **other dosage forms**

Tablets	Capsules	Bottles
275 Mn Annual Installed Capacity	**225 Mn** Annual Installed Capacity	**16 Mn** Annual Installed Capacity
Expandable up to **600 Mn**	Expandable up to **500 Mn**	Expandable up to **32 Mn**

Strong Regulatory Approvals

- **USFDA**
- **MHRA**
- **Health Canada**

Accredited API Manufacturing Facilities

Senores
Committed to Global Wellness!

Senores API Plant I & II

- The two plants have a land parcel of **15,134 sq. ft**. and **230,000 sq. ft**. respectively.
- Employee Strength **– 110+ Employees**
- The facility integrates manufacturing with an advanced **Quality Control Lab** dedicated to testing and releasing all products.
- **17+** Products already **commercialized**.
- **5+** Products in **development**.
- **3 DMFs** under finalization to be filed for triggering the **USFDA audit**.

Unit I

25 MT
Annual Installed Capacity

Unit II

100 MT
Annual Installed Capacity

Site is Approvable by Authorities

GMP

WHO-GMP

USFDA

Great Place to Work with Active Member of Globally recognized Pharma Associations

Senores
Committed to Global Wellness!

Great Place To Work Certified

Active Member of Various **Globally Recognized Pharmaceutical Associations & Working Bodies**

FICCI

ASSOCHAM
Ideate · Innovate · Impact

CII
Confederation of Indian Industry

able
Pursuing Infinite Opportunities
Association of Biotechnology Led Enterprises

GCCI
GUJARAT CHAMBER OF COMMERCE & INDUSTRY

pharmexcil

IDMA

THE INDIAN PHARMACEUTICAL ASSOCIATION (IPA)
...CRUSADE FOR THE PROFESSION

FOPE®
Federation Of Pharma Entrepreneurs

SENORES PHARMACEUTICALS LIMITED

CONTACT US

Senores Pharmaceuticals Limited

CIN: L24290GJ2017PLC100263

Mr. Deval Shah – Whole Time Director & CFO

investors@senorespharma.com

Strategic Growth Advisors Private Limited

CIN: U74140MH2010PTC204285

Mr. Sagar Shroff / Mr. Tanay Shah
sagar.shroff@sgapl.net / tanay.shah@sgapl.net
+91 98205 19303 / +91 98333 91899